Master Alliance Provisions Guide (MAPGuide)

Pfizer – MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement

  • Protecting & sharing information | Publication of Results



5.7. Publications. During the Term, MPP shall submit, and shall direct its Sublicensees to submit, for review and approval any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to the Pfizer no later than forty-five (45) days before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within thirty (30) days of its receipt of such written copy. The Review Period may be extended for an additional thirty (30) days in the event the reviewing Party can, within thirty (30) days of receipt of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. MPP will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 5.7, including International Committee of Medical Journal Editors standards regarding authorship and contributions.